Eliem Therapeutics Inc ELYM announced interim results from its ongoing Period 1 trial of ETX-155 for important depressive problem (MDD) and epilepsy. 
 Subsequent reduce-than-expected drug publicity

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Period 1 trial of ETX-155 for important depressive problem (MDD) and epilepsy. 
 Subsequent reduce-than-expected drug publicity